Skip to main content
Premium Trial:

Request an Annual Quote

Because $999 May Not Keep Investors Happy

David Hamilton has an article at VentureBeat about how viable the business model behind companies like 23andMe will turn out to be. He predicts that these consumer genomics companies will actually get most of their revenue from pharma, which he says are likely to pay for "access to the aggregate genetic information 23andMe amasses from its customers." GTO wonders how many of these customers understand the real details of whatever privacy policy they're given.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.